Cargando…
A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the Mycobacterium avium Complex
Treatment outcomes using the standard regimen (a macrolide, ethambutol, and rifampicin) for Mycobacterium avium complex-pulmonary disease (MAC-PD) remain unsatisfactory. Thus, improved treatment regimens for MAC-PD are required. Clofazimine has recently been revisited as an effective drug against my...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841306/ https://www.ncbi.nlm.nih.gov/pubmed/33519787 http://dx.doi.org/10.3389/fmicb.2020.626216 |
_version_ | 1783643777640955904 |
---|---|
author | Lee, Ju Mi Park, Jiyun Choi, Sangwon Jhun, Byung Woo Kim, Su-Young Jo, Kyung-Wook Hong, Jung Joo Kim, Lee-Han Shin, Sung Jae |
author_facet | Lee, Ju Mi Park, Jiyun Choi, Sangwon Jhun, Byung Woo Kim, Su-Young Jo, Kyung-Wook Hong, Jung Joo Kim, Lee-Han Shin, Sung Jae |
author_sort | Lee, Ju Mi |
collection | PubMed |
description | Treatment outcomes using the standard regimen (a macrolide, ethambutol, and rifampicin) for Mycobacterium avium complex-pulmonary disease (MAC-PD) remain unsatisfactory. Thus, improved treatment regimens for MAC-PD are required. Clofazimine has recently been revisited as an effective drug against mycobacterial infection. We performed a comparison between the standard regimen and an alternative regimen (replacing the rifampicin of the standard regimen with clofazimine) based on the intracellular anti-MAC activities of the individual drugs in a murine model of chronic progressive MAC-pulmonary infection (MAC-PI). The intracellular anti-MAC activities of the individual drugs and their combinations in murine bone marrow-derived macrophages (BMDMs) were determined. The treatment efficacies of the standard and clofazimine-containing regimens were evaluated in mice chronically infected with M. avium by initiating 2- and 4-week treatment at 8 weeks post-infection. Bacterial loads in the lung, spleen, and liver were assessed along with lung inflammation. Insufficient intracellular anti-MAC activity of rifampicin in BMDMs was recorded despite its low in vitro minimum inhibitory concentrations (MICs), whereas optimal intracellular killing activity against all tested MAC strains was achieved with clofazimine. Compared to the standard regimen, the clofazimine-containing regimen significantly reduced CFUs in all organs and achieved marked reductions in lung inflammation. The replacement of rifampicin with clofazimine in the treatment regimen resulted in more favorable outcomes in an animal model of chronic progressive MAC-PI. Intriguingly, 2 weeks of treatment with the clofazimine-containing regimen reduced bacterial loads more effectively than 4 weeks of treatment with the standard regimen in M. avium-infected mice. Thus, the clofazimine-containing regimen also had a treatment-shortening effect. |
format | Online Article Text |
id | pubmed-7841306 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78413062021-01-29 A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the Mycobacterium avium Complex Lee, Ju Mi Park, Jiyun Choi, Sangwon Jhun, Byung Woo Kim, Su-Young Jo, Kyung-Wook Hong, Jung Joo Kim, Lee-Han Shin, Sung Jae Front Microbiol Microbiology Treatment outcomes using the standard regimen (a macrolide, ethambutol, and rifampicin) for Mycobacterium avium complex-pulmonary disease (MAC-PD) remain unsatisfactory. Thus, improved treatment regimens for MAC-PD are required. Clofazimine has recently been revisited as an effective drug against mycobacterial infection. We performed a comparison between the standard regimen and an alternative regimen (replacing the rifampicin of the standard regimen with clofazimine) based on the intracellular anti-MAC activities of the individual drugs in a murine model of chronic progressive MAC-pulmonary infection (MAC-PI). The intracellular anti-MAC activities of the individual drugs and their combinations in murine bone marrow-derived macrophages (BMDMs) were determined. The treatment efficacies of the standard and clofazimine-containing regimens were evaluated in mice chronically infected with M. avium by initiating 2- and 4-week treatment at 8 weeks post-infection. Bacterial loads in the lung, spleen, and liver were assessed along with lung inflammation. Insufficient intracellular anti-MAC activity of rifampicin in BMDMs was recorded despite its low in vitro minimum inhibitory concentrations (MICs), whereas optimal intracellular killing activity against all tested MAC strains was achieved with clofazimine. Compared to the standard regimen, the clofazimine-containing regimen significantly reduced CFUs in all organs and achieved marked reductions in lung inflammation. The replacement of rifampicin with clofazimine in the treatment regimen resulted in more favorable outcomes in an animal model of chronic progressive MAC-PI. Intriguingly, 2 weeks of treatment with the clofazimine-containing regimen reduced bacterial loads more effectively than 4 weeks of treatment with the standard regimen in M. avium-infected mice. Thus, the clofazimine-containing regimen also had a treatment-shortening effect. Frontiers Media S.A. 2021-01-14 /pmc/articles/PMC7841306/ /pubmed/33519787 http://dx.doi.org/10.3389/fmicb.2020.626216 Text en Copyright © 2021 Lee, Park, Choi, Jhun, Kim, Jo, Hong, Kim and Shin. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Lee, Ju Mi Park, Jiyun Choi, Sangwon Jhun, Byung Woo Kim, Su-Young Jo, Kyung-Wook Hong, Jung Joo Kim, Lee-Han Shin, Sung Jae A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the Mycobacterium avium Complex |
title | A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the Mycobacterium avium Complex |
title_full | A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the Mycobacterium avium Complex |
title_fullStr | A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the Mycobacterium avium Complex |
title_full_unstemmed | A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the Mycobacterium avium Complex |
title_short | A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the Mycobacterium avium Complex |
title_sort | clofazimine-containing regimen confers improved treatment outcomes in macrophages and in a murine model of chronic progressive pulmonary infection caused by the mycobacterium avium complex |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841306/ https://www.ncbi.nlm.nih.gov/pubmed/33519787 http://dx.doi.org/10.3389/fmicb.2020.626216 |
work_keys_str_mv | AT leejumi aclofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex AT parkjiyun aclofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex AT choisangwon aclofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex AT jhunbyungwoo aclofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex AT kimsuyoung aclofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex AT jokyungwook aclofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex AT hongjungjoo aclofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex AT kimleehan aclofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex AT shinsungjae aclofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex AT leejumi clofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex AT parkjiyun clofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex AT choisangwon clofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex AT jhunbyungwoo clofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex AT kimsuyoung clofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex AT jokyungwook clofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex AT hongjungjoo clofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex AT kimleehan clofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex AT shinsungjae clofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex |